Senate to vote on von Eschenbach nomination today

Share this article:
The US Senate is scheduled to consider Andrew von Eschenbach’s nomination to head the FDA today. The Senate has scheduled a procedural vote that requires the support of 60 senators to advance the nomination to a full vote, Reuters reported. Several senators have praised von Eschenbach’s qualifications to lead the agency and his nomination cleared a Senate committee in September. But three Republican Senators have blocked a full Senate vote. Senate Finance Committee Chairman Charles Grassley of Iowa said he opposed a von Eschenbach confirmation vote because the FDA failed to cooperate with his investigation of Sanofi-Aventis’ antibiotic Ketek and related reports of liver failure. Sen. Jim DeMint of South Carolina opposed a vote due to his concerns about the safety of the abortion pill RU-486. Sen. David Vitter of Louisiana said he will oppose a vote until prescription drug imports are legalized. Spokespeople for each of the three senators told Reuters early today they still object to a vote on von Eschenbach’s nomination.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.